search
Back to results

Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma (HSP70)

Primary Purpose

Hepatocellular Carcinoma

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Polymorphisms of HSP70 and TNF promoter
Sponsored by
Kaohsiung Medical University Chung-Ho Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hepatocellular Carcinoma focused on measuring heat shock protein70, tumor necrosis factor-alpha promoter, polymorphism

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • History proven HCC patients

Exclusion Criteria:

  • No-definite diagnosed patients

Sites / Locations

  • Kaohsiung Medical University
  • Kaohsiung Medical University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HSP70 and TNF polymorphisms

Arm Description

Outcomes

Primary Outcome Measures

Clinical relevance

Secondary Outcome Measures

Clinical relevance

Full Information

First Posted
February 26, 2008
Last Updated
April 26, 2013
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00769535
Brief Title
Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
Acronym
HSP70
Official Title
Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct sequencing. The clinical relevance of patients will be compared in those with polymorphism and those without.
Detailed Description
Heat shock protein 70 (HSP 70) may be involved in various aspects of immune system including infection, autoimmunity, and tumor immunity. The relationship between HSP70 expression, disease activity and cancer prognosis varied according to type of cancer. The overexpression of HSP70 by tumor cells contributes to tumor behavior. HSP70 is present in normal and abnormal hepatocytes, and was reported to be over-expressed in both hepatoma cell lines and human hepatocellular carcinoma (HCC) tissue. Recent study indicated that HSP70 is a molecular marker during early hepatocarcinogenesis. It is also involved in anti-tumor immunity in HCC.We also investigate the polymorphism of tumor necrosis factor-alpha promoter, and correlated to clinical relevance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
heat shock protein70, tumor necrosis factor-alpha promoter, polymorphism

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HSP70 and TNF polymorphisms
Arm Type
Experimental
Intervention Type
Genetic
Intervention Name(s)
Polymorphisms of HSP70 and TNF promoter
Other Intervention Name(s)
polymorphism of HSP70, polymorphism of tumor necrosis factor-alpha promoter
Intervention Description
To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
Primary Outcome Measure Information:
Title
Clinical relevance
Time Frame
year
Secondary Outcome Measure Information:
Title
Clinical relevance
Time Frame
year

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: History proven HCC patients Exclusion Criteria: No-definite diagnosed patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jung-Fa Tsai, M.D., Ph.D.
Organizational Affiliation
Professor of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaohsiung Medical University
City
Kaohsiung
State/Province
Kaohsiun
ZIP/Postal Code
807
Country
Taiwan
Facility Name
Kaohsiung Medical University
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs